nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Simvastatin—atherosclerosis	0.0702	0.112	CbGbCtD
Loperamide—CYP2C8—Simvastatin—atherosclerosis	0.0532	0.0849	CbGbCtD
Loperamide—CYP2C8—Lovastatin—atherosclerosis	0.052	0.0831	CbGbCtD
Loperamide—CYP2C8—Pravastatin—atherosclerosis	0.052	0.0831	CbGbCtD
Loperamide—CYP2D6—Niacin—atherosclerosis	0.0429	0.0685	CbGbCtD
Loperamide—ABCB1—Ezetimibe—atherosclerosis	0.0387	0.0618	CbGbCtD
Loperamide—ABCB1—Simvastatin—atherosclerosis	0.036	0.0575	CbGbCtD
Loperamide—ABCB1—Lovastatin—atherosclerosis	0.0352	0.0563	CbGbCtD
Loperamide—ABCB1—Pravastatin—atherosclerosis	0.0352	0.0563	CbGbCtD
Loperamide—CYP2D6—Simvastatin—atherosclerosis	0.0339	0.0542	CbGbCtD
Loperamide—CYP2D6—Pravastatin—atherosclerosis	0.0332	0.053	CbGbCtD
Loperamide—CYP2D6—Lovastatin—atherosclerosis	0.0332	0.053	CbGbCtD
Loperamide—CYP3A4—Rosuvastatin—atherosclerosis	0.0232	0.0371	CbGbCtD
Loperamide—CYP3A4—Ezetimibe—atherosclerosis	0.0232	0.0371	CbGbCtD
Loperamide—CYP3A4—Simvastatin—atherosclerosis	0.0216	0.0344	CbGbCtD
Loperamide—CYP3A4—Lovastatin—atherosclerosis	0.0211	0.0337	CbGbCtD
Loperamide—CYP3A4—Pravastatin—atherosclerosis	0.0211	0.0337	CbGbCtD
Loperamide—Distention—Pravastatin—atherosclerosis	0.00919	0.0767	CcSEcCtD
Loperamide—POMC—blood vessel—atherosclerosis	0.00591	0.164	CbGeAlD
Loperamide—POMC—connective tissue—atherosclerosis	0.00303	0.084	CbGeAlD
Loperamide—POMC—cardiovascular system—atherosclerosis	0.00263	0.0731	CbGeAlD
Loperamide—POMC—adipose tissue—atherosclerosis	0.00232	0.0644	CbGeAlD
Loperamide—CALM2—artery—atherosclerosis	0.00207	0.0574	CbGeAlD
Loperamide—CALM1—artery—atherosclerosis	0.00206	0.0572	CbGeAlD
Loperamide—CALM2—endothelium—atherosclerosis	0.00175	0.0485	CbGeAlD
Loperamide—CALM1—endothelium—atherosclerosis	0.00174	0.0483	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.00167	0.014	CcSEcCtD
Loperamide—Dermatitis bullous—Niacin—atherosclerosis	0.00167	0.0139	CcSEcCtD
Loperamide—POMC—liver—atherosclerosis	0.00163	0.0452	CbGeAlD
Loperamide—CALM2—blood vessel—atherosclerosis	0.00161	0.0447	CbGeAlD
Loperamide—CALM1—blood vessel—atherosclerosis	0.00161	0.0445	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00157	0.0131	CcSEcCtD
Loperamide—Urinary retention—Niacin—atherosclerosis	0.00152	0.0127	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.00142	0.0118	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00142	0.0118	CcSEcCtD
Loperamide—Abdominal distension—Niacin—atherosclerosis	0.00139	0.0116	CcSEcCtD
Loperamide—Abdominal distension—Pravastatin—atherosclerosis	0.00137	0.0114	CcSEcCtD
Loperamide—Cetirizine—HRH1—atherosclerosis	0.00133	0.172	CrCbGaD
Loperamide—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.00133	0.0111	CcSEcCtD
Loperamide—Flatulence—Rosuvastatin—atherosclerosis	0.0013	0.0109	CcSEcCtD
Loperamide—Erythema multiforme—Lovastatin—atherosclerosis	0.00122	0.0101	CcSEcCtD
Loperamide—Angioedema—Rosuvastatin—atherosclerosis	0.00121	0.0101	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.0012	0.01	CcSEcCtD
Loperamide—Erythema multiforme—Ezetimibe—atherosclerosis	0.00119	0.00995	CcSEcCtD
Loperamide—Buclizine—HRH1—atherosclerosis	0.00116	0.15	CrCbGaD
Loperamide—Immune system disorder—Ezetimibe—atherosclerosis	0.00114	0.0095	CcSEcCtD
Loperamide—Erythema multiforme—Simvastatin—atherosclerosis	0.00114	0.00949	CcSEcCtD
Loperamide—Meclizine—HRH1—atherosclerosis	0.00111	0.143	CrCbGaD
Loperamide—Flatulence—Lovastatin—atherosclerosis	0.0011	0.0092	CcSEcCtD
Loperamide—Flatulence—Ezetimibe—atherosclerosis	0.00108	0.00903	CcSEcCtD
Loperamide—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00106	0.00882	CcSEcCtD
Loperamide—Clemastine—HRH1—atherosclerosis	0.00104	0.135	CrCbGaD
Loperamide—Flatulence—Simvastatin—atherosclerosis	0.00103	0.00861	CcSEcCtD
Loperamide—Erythema multiforme—Pravastatin—atherosclerosis	0.00103	0.00858	CcSEcCtD
Loperamide—Angioedema—Lovastatin—atherosclerosis	0.00102	0.00853	CcSEcCtD
Loperamide—Angioedema—Ezetimibe—atherosclerosis	0.001	0.00837	CcSEcCtD
Loperamide—Clofedanol—HRH1—atherosclerosis	0.00099	0.128	CrCbGaD
Loperamide—Angioedema—Simvastatin—atherosclerosis	0.000957	0.00798	CcSEcCtD
Loperamide—Dyspepsia—Rosuvastatin—atherosclerosis	0.000949	0.00792	CcSEcCtD
Loperamide—Flatulence—Niacin—atherosclerosis	0.000947	0.0079	CcSEcCtD
Loperamide—Discomfort—Lovastatin—atherosclerosis	0.000942	0.00786	CcSEcCtD
Loperamide—Flatulence—Pravastatin—atherosclerosis	0.000933	0.00778	CcSEcCtD
Loperamide—Dry mouth—Lovastatin—atherosclerosis	0.000932	0.00778	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000928	0.00774	CcSEcCtD
Loperamide—Discomfort—Ezetimibe—atherosclerosis	0.000923	0.0077	CcSEcCtD
Loperamide—Constipation—Rosuvastatin—atherosclerosis	0.000922	0.00769	CcSEcCtD
Loperamide—Dry mouth—Ezetimibe—atherosclerosis	0.000914	0.00763	CcSEcCtD
Loperamide—Anaphylactic shock—Lovastatin—atherosclerosis	0.000914	0.00762	CcSEcCtD
Loperamide—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000896	0.00748	CcSEcCtD
Loperamide—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000881	0.00735	CcSEcCtD
Loperamide—Discomfort—Simvastatin—atherosclerosis	0.000881	0.00735	CcSEcCtD
Loperamide—Nervous system disorder—Ezetimibe—atherosclerosis	0.000879	0.00733	CcSEcCtD
Loperamide—Angioedema—Niacin—atherosclerosis	0.000878	0.00733	CcSEcCtD
Loperamide—Skin disorder—Ezetimibe—atherosclerosis	0.00087	0.00726	CcSEcCtD
Loperamide—Angioedema—Pravastatin—atherosclerosis	0.000865	0.00722	CcSEcCtD
Loperamide—Urticaria—Rosuvastatin—atherosclerosis	0.000856	0.00714	CcSEcCtD
Loperamide—Anaphylactic shock—Simvastatin—atherosclerosis	0.000854	0.00713	CcSEcCtD
Loperamide—Abdominal pain—Rosuvastatin—atherosclerosis	0.000852	0.00711	CcSEcCtD
Loperamide—Loss of consciousness—Niacin—atherosclerosis	0.000845	0.00705	CcSEcCtD
Loperamide—CALM2—connective tissue—atherosclerosis	0.000827	0.0229	CbGeAlD
Loperamide—CALM1—connective tissue—atherosclerosis	0.000823	0.0228	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000813	0.00678	CcSEcCtD
Loperamide—CALM3—adipose tissue—atherosclerosis	0.000808	0.0224	CbGeAlD
Loperamide—Dyspepsia—Lovastatin—atherosclerosis	0.000804	0.00671	CcSEcCtD
Loperamide—Dry mouth—Niacin—atherosclerosis	0.0008	0.00668	CcSEcCtD
Loperamide—Discomfort—Pravastatin—atherosclerosis	0.000796	0.00664	CcSEcCtD
Loperamide—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000794	0.00663	CcSEcCtD
Loperamide—Dyspepsia—Ezetimibe—atherosclerosis	0.000789	0.00658	CcSEcCtD
Loperamide—Fatigue—Lovastatin—atherosclerosis	0.000788	0.00657	CcSEcCtD
Loperamide—Anaphylactic shock—Niacin—atherosclerosis	0.000785	0.00655	CcSEcCtD
Loperamide—Constipation—Lovastatin—atherosclerosis	0.000781	0.00652	CcSEcCtD
Loperamide—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000774	0.00645	CcSEcCtD
Loperamide—Asthenia—Rosuvastatin—atherosclerosis	0.000773	0.00645	CcSEcCtD
Loperamide—Anaphylactic shock—Pravastatin—atherosclerosis	0.000773	0.00645	CcSEcCtD
Loperamide—Fatigue—Ezetimibe—atherosclerosis	0.000773	0.00645	CcSEcCtD
Loperamide—Constipation—Ezetimibe—atherosclerosis	0.000766	0.00639	CcSEcCtD
Loperamide—Pruritus—Rosuvastatin—atherosclerosis	0.000763	0.00636	CcSEcCtD
Loperamide—Skin disorder—Niacin—atherosclerosis	0.000762	0.00636	CcSEcCtD
Loperamide—Dyspepsia—Simvastatin—atherosclerosis	0.000752	0.00628	CcSEcCtD
Loperamide—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000747	0.00623	CcSEcCtD
Loperamide—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000738	0.00615	CcSEcCtD
Loperamide—Diarrhoea—Rosuvastatin—atherosclerosis	0.000738	0.00615	CcSEcCtD
Loperamide—Fatigue—Simvastatin—atherosclerosis	0.000737	0.00615	CcSEcCtD
Loperamide—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000733	0.00611	CcSEcCtD
Loperamide—Constipation—Simvastatin—atherosclerosis	0.000731	0.0061	CcSEcCtD
Loperamide—Urticaria—Lovastatin—atherosclerosis	0.000726	0.00605	CcSEcCtD
Loperamide—Fexofenadine—HRH1—atherosclerosis	0.000724	0.0935	CrCbGaD
Loperamide—Abdominal pain—Lovastatin—atherosclerosis	0.000722	0.00603	CcSEcCtD
Loperamide—CALM2—cardiovascular system—atherosclerosis	0.00072	0.02	CbGeAlD
Loperamide—CALM1—cardiovascular system—atherosclerosis	0.000716	0.0199	CbGeAlD
Loperamide—Dizziness—Rosuvastatin—atherosclerosis	0.000713	0.00595	CcSEcCtD
Loperamide—Urticaria—Ezetimibe—atherosclerosis	0.000712	0.00594	CcSEcCtD
Loperamide—Abdominal pain—Ezetimibe—atherosclerosis	0.000708	0.00591	CcSEcCtD
Loperamide—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000699	0.00583	CcSEcCtD
Loperamide—Somnolence—Niacin—atherosclerosis	0.000698	0.00582	CcSEcCtD
Loperamide—Dyspepsia—Niacin—atherosclerosis	0.000691	0.00576	CcSEcCtD
Loperamide—Dyspepsia—Pravastatin—atherosclerosis	0.00068	0.00567	CcSEcCtD
Loperamide—Rash—Rosuvastatin—atherosclerosis	0.00068	0.00567	CcSEcCtD
Loperamide—Dermatitis—Rosuvastatin—atherosclerosis	0.000679	0.00567	CcSEcCtD
Loperamide—Urticaria—Simvastatin—atherosclerosis	0.000679	0.00566	CcSEcCtD
Loperamide—Gastrointestinal disorder—Niacin—atherosclerosis	0.000677	0.00565	CcSEcCtD
Loperamide—Abdominal pain—Simvastatin—atherosclerosis	0.000675	0.00564	CcSEcCtD
Loperamide—Headache—Rosuvastatin—atherosclerosis	0.000675	0.00563	CcSEcCtD
Loperamide—Hypersensitivity—Lovastatin—atherosclerosis	0.000673	0.00562	CcSEcCtD
Loperamide—Fatigue—Pravastatin—atherosclerosis	0.000666	0.00556	CcSEcCtD
Loperamide—Constipation—Pravastatin—atherosclerosis	0.000661	0.00551	CcSEcCtD
Loperamide—Hypersensitivity—Ezetimibe—atherosclerosis	0.00066	0.00551	CcSEcCtD
Loperamide—Asthenia—Lovastatin—atherosclerosis	0.000655	0.00547	CcSEcCtD
Loperamide—Pruritus—Lovastatin—atherosclerosis	0.000646	0.00539	CcSEcCtD
Loperamide—Asthenia—Ezetimibe—atherosclerosis	0.000643	0.00536	CcSEcCtD
Loperamide—Gastrointestinal pain—Niacin—atherosclerosis	0.000642	0.00535	CcSEcCtD
Loperamide—ABCB1—blood vessel—atherosclerosis	0.000641	0.0178	CbGeAlD
Loperamide—Nausea—Rosuvastatin—atherosclerosis	0.00064	0.00534	CcSEcCtD
Loperamide—CALM2—adipose tissue—atherosclerosis	0.000635	0.0176	CbGeAlD
Loperamide—Pruritus—Ezetimibe—atherosclerosis	0.000634	0.00529	CcSEcCtD
Loperamide—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000632	0.00527	CcSEcCtD
Loperamide—CALM1—adipose tissue—atherosclerosis	0.000632	0.0175	CbGeAlD
Loperamide—Hypersensitivity—Simvastatin—atherosclerosis	0.00063	0.00525	CcSEcCtD
Loperamide—Diarrhoea—Lovastatin—atherosclerosis	0.000625	0.00521	CcSEcCtD
Loperamide—Urticaria—Niacin—atherosclerosis	0.000623	0.0052	CcSEcCtD
Loperamide—Abdominal pain—Niacin—atherosclerosis	0.00062	0.00517	CcSEcCtD
Loperamide—Urticaria—Pravastatin—atherosclerosis	0.000614	0.00512	CcSEcCtD
Loperamide—Asthenia—Simvastatin—atherosclerosis	0.000613	0.00511	CcSEcCtD
Loperamide—Diarrhoea—Ezetimibe—atherosclerosis	0.000613	0.00511	CcSEcCtD
Loperamide—Abdominal pain—Pravastatin—atherosclerosis	0.000611	0.0051	CcSEcCtD
Loperamide—Pruritus—Simvastatin—atherosclerosis	0.000605	0.00504	CcSEcCtD
Loperamide—Dizziness—Lovastatin—atherosclerosis	0.000604	0.00504	CcSEcCtD
Loperamide—Dizziness—Ezetimibe—atherosclerosis	0.000593	0.00494	CcSEcCtD
Loperamide—Diarrhoea—Simvastatin—atherosclerosis	0.000585	0.00488	CcSEcCtD
Loperamide—Vomiting—Lovastatin—atherosclerosis	0.000581	0.00485	CcSEcCtD
Loperamide—Hypersensitivity—Niacin—atherosclerosis	0.000578	0.00482	CcSEcCtD
Loperamide—Rash—Lovastatin—atherosclerosis	0.000576	0.00481	CcSEcCtD
Loperamide—Dermatitis—Lovastatin—atherosclerosis	0.000575	0.0048	CcSEcCtD
Loperamide—Headache—Lovastatin—atherosclerosis	0.000572	0.00477	CcSEcCtD
Loperamide—Vomiting—Ezetimibe—atherosclerosis	0.00057	0.00475	CcSEcCtD
Loperamide—Hypersensitivity—Pravastatin—atherosclerosis	0.000569	0.00475	CcSEcCtD
Loperamide—CALM3—liver—atherosclerosis	0.000567	0.0157	CbGeAlD
Loperamide—Dizziness—Simvastatin—atherosclerosis	0.000565	0.00471	CcSEcCtD
Loperamide—Rash—Ezetimibe—atherosclerosis	0.000565	0.00471	CcSEcCtD
Loperamide—Dermatitis—Ezetimibe—atherosclerosis	0.000564	0.00471	CcSEcCtD
Loperamide—Asthenia—Niacin—atherosclerosis	0.000563	0.0047	CcSEcCtD
Loperamide—Headache—Ezetimibe—atherosclerosis	0.000561	0.00468	CcSEcCtD
Loperamide—Pruritus—Niacin—atherosclerosis	0.000555	0.00463	CcSEcCtD
Loperamide—Asthenia—Pravastatin—atherosclerosis	0.000554	0.00462	CcSEcCtD
Loperamide—Pruritus—Pravastatin—atherosclerosis	0.000547	0.00456	CcSEcCtD
Loperamide—Vomiting—Simvastatin—atherosclerosis	0.000543	0.00453	CcSEcCtD
Loperamide—Nausea—Lovastatin—atherosclerosis	0.000543	0.00453	CcSEcCtD
Loperamide—Rash—Simvastatin—atherosclerosis	0.000539	0.00449	CcSEcCtD
Loperamide—Dermatitis—Simvastatin—atherosclerosis	0.000538	0.00449	CcSEcCtD
Loperamide—Diarrhoea—Niacin—atherosclerosis	0.000537	0.00448	CcSEcCtD
Loperamide—Headache—Simvastatin—atherosclerosis	0.000535	0.00447	CcSEcCtD
Loperamide—CYP2B6—cardiovascular system—atherosclerosis	0.000535	0.0148	CbGeAlD
Loperamide—Nausea—Ezetimibe—atherosclerosis	0.000532	0.00444	CcSEcCtD
Loperamide—Diarrhoea—Pravastatin—atherosclerosis	0.000529	0.00441	CcSEcCtD
Loperamide—Dizziness—Niacin—atherosclerosis	0.000519	0.00433	CcSEcCtD
Loperamide—Dizziness—Pravastatin—atherosclerosis	0.000511	0.00426	CcSEcCtD
Loperamide—Nausea—Simvastatin—atherosclerosis	0.000508	0.00423	CcSEcCtD
Loperamide—Haloperidol—HRH1—atherosclerosis	0.000504	0.065	CrCbGaD
Loperamide—Vomiting—Niacin—atherosclerosis	0.000499	0.00416	CcSEcCtD
Loperamide—Rash—Niacin—atherosclerosis	0.000495	0.00413	CcSEcCtD
Loperamide—Dermatitis—Niacin—atherosclerosis	0.000494	0.00412	CcSEcCtD
Loperamide—Headache—Niacin—atherosclerosis	0.000492	0.0041	CcSEcCtD
Loperamide—Vomiting—Pravastatin—atherosclerosis	0.000491	0.0041	CcSEcCtD
Loperamide—Rash—Pravastatin—atherosclerosis	0.000487	0.00406	CcSEcCtD
Loperamide—Dermatitis—Pravastatin—atherosclerosis	0.000487	0.00406	CcSEcCtD
Loperamide—Headache—Pravastatin—atherosclerosis	0.000484	0.00404	CcSEcCtD
Loperamide—Nausea—Niacin—atherosclerosis	0.000466	0.00389	CcSEcCtD
Loperamide—Nausea—Pravastatin—atherosclerosis	0.000459	0.00383	CcSEcCtD
Loperamide—CALM2—liver—atherosclerosis	0.000445	0.0123	CbGeAlD
Loperamide—CALM1—liver—atherosclerosis	0.000443	0.0123	CbGeAlD
Loperamide—Toremifene—ESR1—atherosclerosis	0.00043	0.0555	CrCbGaD
Loperamide—CYP2C8—liver—atherosclerosis	0.000369	0.0102	CbGeAlD
Loperamide—CYP2B6—liver—atherosclerosis	0.000331	0.00917	CbGeAlD
Loperamide—ABCB1—cardiovascular system—atherosclerosis	0.000286	0.00793	CbGeAlD
Loperamide—Tamoxifen—ESR2—atherosclerosis	0.000279	0.036	CrCbGaD
Loperamide—ABCB1—adipose tissue—atherosclerosis	0.000252	0.00699	CbGeAlD
Loperamide—CYP3A4—liver—atherosclerosis	0.00025	0.00693	CbGeAlD
Loperamide—CYP2D6—liver—atherosclerosis	0.000246	0.00682	CbGeAlD
Loperamide—ABCB1—liver—atherosclerosis	0.000177	0.0049	CbGeAlD
Loperamide—Tamoxifen—ESR1—atherosclerosis	0.000172	0.0221	CrCbGaD
Loperamide—CYP2B6—Metabolism—PPARG—atherosclerosis	6.71e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NOS3—atherosclerosis	6.7e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNG—atherosclerosis	6.7e-06	3.19e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNG—atherosclerosis	6.7e-06	3.19e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOB—atherosclerosis	6.69e-06	3.18e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AGT—atherosclerosis	6.65e-06	3.16e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—GPX1—atherosclerosis	6.61e-06	3.14e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CETP—atherosclerosis	6.6e-06	3.14e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—INS—atherosclerosis	6.58e-06	3.13e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PDGFB—atherosclerosis	6.55e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CG—atherosclerosis	6.54e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CG—atherosclerosis	6.54e-06	3.11e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PPARG—atherosclerosis	6.53e-06	3.1e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOE—atherosclerosis	6.52e-06	3.1e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GSTM1—atherosclerosis	6.5e-06	3.09e-05	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	6.5e-06	3.09e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NOS3—atherosclerosis	6.48e-06	3.08e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NOS3—atherosclerosis	6.48e-06	3.08e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	6.46e-06	3.07e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—CAV1—atherosclerosis	6.46e-06	3.07e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOA1—atherosclerosis	6.44e-06	3.06e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CD36—atherosclerosis	6.44e-06	3.06e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—INS—atherosclerosis	6.4e-06	3.04e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—STAT3—atherosclerosis	6.4e-06	3.04e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—atherosclerosis	6.4e-06	3.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AGT—atherosclerosis	6.39e-06	3.04e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—LPL—atherosclerosis	6.38e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—AKT1—atherosclerosis	6.36e-06	3.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PDGFB—atherosclerosis	6.34e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PDGFB—atherosclerosis	6.34e-06	3.01e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.32e-06	3e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PPARG—atherosclerosis	6.31e-06	3e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PPARG—atherosclerosis	6.31e-06	3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOE—atherosclerosis	6.27e-06	2.98e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—LEP—atherosclerosis	6.27e-06	2.98e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—GPX1—atherosclerosis	6.23e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—atherosclerosis	6.21e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CAV1—atherosclerosis	6.21e-06	2.95e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOA1—atherosclerosis	6.19e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—INS—atherosclerosis	6.19e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—INS—atherosclerosis	6.19e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AGT—atherosclerosis	6.19e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AGT—atherosclerosis	6.19e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1B—atherosclerosis	6.18e-06	2.94e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—AKT1—atherosclerosis	6.16e-06	2.93e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—AKT1—atherosclerosis	6.16e-06	2.93e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—PTGS2—atherosclerosis	6.13e-06	2.91e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	6.11e-06	2.91e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—MTHFR—atherosclerosis	6.1e-06	2.9e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—atherosclerosis	6.08e-06	2.89e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CD36—atherosclerosis	6.07e-06	2.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOE—atherosclerosis	6.06e-06	2.88e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—LEP—atherosclerosis	6.06e-06	2.88e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOE—atherosclerosis	6.06e-06	2.88e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—LEP—atherosclerosis	6.06e-06	2.88e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ALB—atherosclerosis	6.03e-06	2.87e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	6.02e-06	2.86e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—atherosclerosis	6.01e-06	2.86e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—atherosclerosis	6.01e-06	2.86e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CAV1—atherosclerosis	6e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CAV1—atherosclerosis	6e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOA1—atherosclerosis	5.99e-06	2.85e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOA1—atherosclerosis	5.99e-06	2.85e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARA—atherosclerosis	5.98e-06	2.84e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ESR1—atherosclerosis	5.98e-06	2.84e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1B—atherosclerosis	5.98e-06	2.84e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1B—atherosclerosis	5.98e-06	2.84e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.97e-06	2.84e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	5.93e-06	2.82e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—PTGS2—atherosclerosis	5.93e-06	2.82e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—PTGS2—atherosclerosis	5.93e-06	2.82e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	5.92e-06	2.81e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—F2—atherosclerosis	5.91e-06	2.81e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	5.9e-06	2.81e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CG—atherosclerosis	5.88e-06	2.8e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ALB—atherosclerosis	5.87e-06	2.79e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AGT—atherosclerosis	5.8e-06	2.76e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ESR1—atherosclerosis	5.79e-06	2.75e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ESR1—atherosclerosis	5.79e-06	2.75e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—NOS3—atherosclerosis	5.77e-06	2.74e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NFKB1—atherosclerosis	5.76e-06	2.74e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—MTHFR—atherosclerosis	5.75e-06	2.73e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—AKT1—atherosclerosis	5.73e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—F2—atherosclerosis	5.72e-06	2.72e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—F2—atherosclerosis	5.72e-06	2.72e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOE—atherosclerosis	5.68e-06	2.7e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PPARG—atherosclerosis	5.68e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ALB—atherosclerosis	5.68e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ALB—atherosclerosis	5.68e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK8—atherosclerosis	5.66e-06	2.69e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CG—atherosclerosis	5.65e-06	2.69e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARA—atherosclerosis	5.64e-06	2.68e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CAV1—atherosclerosis	5.63e-06	2.67e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—NOS3—atherosclerosis	5.61e-06	2.67e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOA1—atherosclerosis	5.61e-06	2.67e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NFKB1—atherosclerosis	5.57e-06	2.65e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NFKB1—atherosclerosis	5.57e-06	2.65e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—INS—atherosclerosis	5.57e-06	2.65e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—AKT1—atherosclerosis	5.54e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—AKT1—atherosclerosis	5.54e-06	2.63e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—AKT1—atherosclerosis	5.5e-06	2.62e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK8—atherosclerosis	5.48e-06	2.61e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK8—atherosclerosis	5.48e-06	2.61e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CG—atherosclerosis	5.47e-06	2.6e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CG—atherosclerosis	5.47e-06	2.6e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	5.46e-06	2.6e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AGT—atherosclerosis	5.46e-06	2.6e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—NOS3—atherosclerosis	5.43e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—NOS3—atherosclerosis	5.43e-06	2.58e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MAPK3—atherosclerosis	5.42e-06	2.57e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—STAT3—atherosclerosis	5.41e-06	2.57e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—INS—atherosclerosis	5.35e-06	2.54e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOE—atherosclerosis	5.35e-06	2.54e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—AKT1—atherosclerosis	5.32e-06	2.53e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—AKT1—atherosclerosis	5.32e-06	2.53e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.32e-06	2.53e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CAV1—atherosclerosis	5.3e-06	2.52e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOA1—atherosclerosis	5.29e-06	2.51e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTGS2—atherosclerosis	5.28e-06	2.51e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL2—atherosclerosis	5.27e-06	2.5e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MAPK3—atherosclerosis	5.24e-06	2.49e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MAPK3—atherosclerosis	5.24e-06	2.49e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—STAT3—atherosclerosis	5.18e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—INS—atherosclerosis	5.18e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—INS—atherosclerosis	5.18e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1—atherosclerosis	5.18e-06	2.46e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	5.17e-06	2.46e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—atherosclerosis	5.13e-06	2.44e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CG—atherosclerosis	5.12e-06	2.44e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—atherosclerosis	5.1e-06	2.43e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—atherosclerosis	5.1e-06	2.42e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—atherosclerosis	5.09e-06	2.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—atherosclerosis	5.09e-06	2.42e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	5.01e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—atherosclerosis	5.01e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—atherosclerosis	5.01e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—atherosclerosis	5.01e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—atherosclerosis	5.01e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—atherosclerosis	4.97e-06	2.36e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—atherosclerosis	4.97e-06	2.36e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK3—atherosclerosis	4.95e-06	2.35e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PPARG—atherosclerosis	4.95e-06	2.35e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SERPINE1—atherosclerosis	4.92e-06	2.34e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—NOS3—atherosclerosis	4.88e-06	2.32e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—INS—atherosclerosis	4.85e-06	2.31e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.83e-06	2.3e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK3—atherosclerosis	4.79e-06	2.28e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK3—atherosclerosis	4.79e-06	2.28e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—atherosclerosis	4.78e-06	2.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SERPINE1—atherosclerosis	4.76e-06	2.26e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SERPINE1—atherosclerosis	4.76e-06	2.26e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—atherosclerosis	4.7e-06	2.24e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NOS3—atherosclerosis	4.69e-06	2.23e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PPARG—atherosclerosis	4.66e-06	2.22e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—atherosclerosis	4.63e-06	2.2e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—atherosclerosis	4.63e-06	2.2e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—INS—atherosclerosis	4.57e-06	2.17e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK3—atherosclerosis	4.57e-06	2.17e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.56e-06	2.17e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NOS3—atherosclerosis	4.54e-06	2.16e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NOS3—atherosclerosis	4.54e-06	2.16e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—atherosclerosis	4.47e-06	2.13e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—atherosclerosis	4.47e-06	2.12e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—atherosclerosis	4.45e-06	2.11e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—atherosclerosis	4.43e-06	2.11e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK3—atherosclerosis	4.42e-06	2.1e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK3—atherosclerosis	4.42e-06	2.1e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOB—atherosclerosis	4.37e-06	2.08e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—atherosclerosis	4.29e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—atherosclerosis	4.29e-06	2.04e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NOS3—atherosclerosis	4.25e-06	2.02e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.25e-06	2.02e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—atherosclerosis	4.19e-06	1.99e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—LPL—atherosclerosis	4.17e-06	1.98e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—atherosclerosis	4.16e-06	1.98e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—atherosclerosis	4.12e-06	1.96e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GPX1—atherosclerosis	4.07e-06	1.94e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—atherosclerosis	4.03e-06	1.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—atherosclerosis	4.03e-06	1.91e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NOS3—atherosclerosis	4.01e-06	1.91e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CD36—atherosclerosis	3.97e-06	1.89e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—atherosclerosis	3.96e-06	1.88e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—atherosclerosis	3.89e-06	1.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—atherosclerosis	3.83e-06	1.82e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—atherosclerosis	3.83e-06	1.82e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—atherosclerosis	3.78e-06	1.8e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—atherosclerosis	3.77e-06	1.79e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.76e-06	1.79e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NFKB1—atherosclerosis	3.73e-06	1.77e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARA—atherosclerosis	3.69e-06	1.75e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.67e-06	1.74e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK8—atherosclerosis	3.66e-06	1.74e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—atherosclerosis	3.65e-06	1.74e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—atherosclerosis	3.64e-06	1.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—atherosclerosis	3.64e-06	1.73e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—atherosclerosis	3.62e-06	1.72e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NFKB1—atherosclerosis	3.6e-06	1.71e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NFKB1—atherosclerosis	3.6e-06	1.71e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AGT—atherosclerosis	3.57e-06	1.7e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK8—atherosclerosis	3.54e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK8—atherosclerosis	3.54e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—atherosclerosis	3.53e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—atherosclerosis	3.53e-06	1.68e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—atherosclerosis	3.5e-06	1.66e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—atherosclerosis	3.5e-06	1.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOE—atherosclerosis	3.5e-06	1.66e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—atherosclerosis	3.49e-06	1.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CAV1—atherosclerosis	3.47e-06	1.65e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOA1—atherosclerosis	3.46e-06	1.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—atherosclerosis	3.38e-06	1.61e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—atherosclerosis	3.35e-06	1.59e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—atherosclerosis	3.34e-06	1.59e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—atherosclerosis	3.34e-06	1.59e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—atherosclerosis	3.27e-06	1.56e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—atherosclerosis	3.27e-06	1.56e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—atherosclerosis	3.24e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—atherosclerosis	3.24e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—atherosclerosis	3.23e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—atherosclerosis	3.23e-06	1.54e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—atherosclerosis	3.23e-06	1.53e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—atherosclerosis	3.23e-06	1.53e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK3—atherosclerosis	3.2e-06	1.52e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.16e-06	1.5e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—atherosclerosis	3.1e-06	1.48e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK3—atherosclerosis	3.09e-06	1.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK3—atherosclerosis	3.09e-06	1.47e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—atherosclerosis	3.08e-06	1.46e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARG—atherosclerosis	3.05e-06	1.45e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—atherosclerosis	3e-06	1.43e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—atherosclerosis	3e-06	1.43e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—INS—atherosclerosis	2.99e-06	1.42e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—atherosclerosis	2.98e-06	1.42e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—atherosclerosis	2.98e-06	1.42e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—atherosclerosis	2.74e-06	1.3e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—atherosclerosis	2.65e-06	1.26e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NOS3—atherosclerosis	2.62e-06	1.25e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—atherosclerosis	2.58e-06	1.23e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—atherosclerosis	2.5e-06	1.19e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—atherosclerosis	2.5e-06	1.19e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.4e-06	1.14e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—atherosclerosis	2.34e-06	1.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—atherosclerosis	2.26e-06	1.08e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—atherosclerosis	2.26e-06	1.08e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—atherosclerosis	2.24e-06	1.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—atherosclerosis	2.16e-06	1.03e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—atherosclerosis	2.09e-06	9.92e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—atherosclerosis	2.09e-06	9.92e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—atherosclerosis	1.96e-06	9.3e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—atherosclerosis	1.84e-06	8.76e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—atherosclerosis	1.2e-06	5.73e-06	CbGpPWpGaD
